🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting over 82 million new cases each year. Particularly high rates are observed in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options presently on offer.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, marketed under the name a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This approval signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Global Access

According to results detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The trial enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the ability to license and sell the drug in many developing nations.

Clinicians directly involved have shared positive views. Access to a one-pill regimen of this kind is described as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea globally.